科伦药业
(002422)
| 流通市值：469.07亿 | | | 总市值：574.02亿 |
| 流通股本：13.06亿 | | | 总股本：15.98亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,389,897,045 | 21,812,414,489 | 16,788,775,173 | 11,827,102,257 |
| 营业收入 | 4,389,897,045 | 21,812,414,489 | 16,788,775,173 | 11,827,102,257 |
| 二、营业总成本 | 3,728,008,892 | 17,850,873,646 | 13,414,966,751 | 9,235,465,674 |
| 营业成本 | 2,253,369,848 | 10,536,820,557 | 7,973,339,959 | 5,460,300,833 |
| 税金及附加 | 53,276,967 | 276,224,683 | 208,890,927 | 137,116,833 |
| 销售费用 | 631,306,696 | 3,492,619,258 | 2,614,400,264 | 1,918,281,105 |
| 管理费用 | 301,812,127 | 1,308,491,117 | 979,692,555 | 614,302,424 |
| 研发费用 | 484,116,428 | 2,170,538,644 | 1,584,138,271 | 1,078,120,396 |
| 财务费用 | 4,126,826 | 66,179,387 | 54,504,775 | 27,344,083 |
| 其中:利息费用 | 26,524,013 | 151,624,891 | 123,591,837 | 89,506,124 |
| 其中:利息收入 | 12,674,548 | 71,603,649 | 55,953,080 | 40,964,765 |
| 加:公允价值变动收益 | 7,630,072 | 19,898,352 | 13,677,065 | 5,465,160 |
| 加:投资收益 | 61,314,415 | 345,018,134 | 288,265,130 | 213,759,100 |
| 资产处置收益 | 597,484 | 807,537 | 879,447 | 1,371,060 |
| 资产减值损失(新) | - | -130,590,378 | -30,499,004 | -26,047,377 |
| 信用减值损失(新) | -6,412,142 | -109,130,422 | -76,794,845 | -69,697,693 |
| 其他收益 | 68,719,707 | 338,777,395 | 240,643,276 | 195,455,017 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 793,737,689 | 4,426,321,461 | 3,809,979,491 | 2,911,941,850 |
| 加:营业外收入 | 1,070,451 | 8,810,007 | 6,162,674 | 3,054,053 |
| 减:营业外支出 | 21,623,438 | 149,772,644 | 110,480,202 | 49,928,518 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 773,184,702 | 4,285,358,824 | 3,705,661,963 | 2,865,067,385 |
| 减:所得税费用 | 113,597,226 | 923,404,431 | 784,656,386 | 649,288,497 |
| 六、净利润 | 659,587,476 | 3,361,954,393 | 2,921,005,577 | 2,215,778,888 |
| 持续经营净利润 | 659,587,476 | 3,361,954,393 | 2,921,005,577 | 2,215,778,888 |
| 归属于母公司股东的净利润 | 584,242,512 | 2,935,892,103 | 2,470,927,259 | 1,800,111,225 |
| 少数股东损益 | 75,344,964 | 426,062,290 | 450,078,318 | 415,667,663 |
| (一)基本每股收益 | 0.37 | 1.86 | 1.57 | 1.15 |
| (二)稀释每股收益 | 0.37 | 1.86 | 1.57 | 1.15 |
| 八、其他综合收益 | -6,264,066 | 11,139,131 | -17,620,214 | 20,299,128 |
| 归属于母公司股东的其他综合收益 | -7,809,259 | 14,170,642 | -13,921,396 | 20,148,034 |
| 九、综合收益总额 | 653,323,410 | 3,373,093,524 | 2,903,385,363 | 2,236,078,016 |
| 归属于母公司股东的综合收益总额 | 576,433,253 | 2,950,062,745 | 2,457,005,863 | 1,820,259,259 |
| 归属于少数股东的综合收益总额 | 76,890,157 | 423,030,779 | 446,379,500 | 415,818,757 |
| 公告日期 | 2025-04-30 | 2025-04-24 | 2024-10-29 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |